Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 1,149,209	$ 1,277,768
General and administrative	1,403,324	834,679
General and administrative affiliates	1,247,679	324,094
Total operating expenses	3,800,212	2,436,541
Loss from operations	(3,800,212)	(2,436,541)
Other expenses:
Other income		300,000
Loss of issuance	(212,458)
Interest expense	(193,191)	(207,117)
Amortization of Intellectual Property	(8,285)	(3,644)
Debt discount amortization and amortization of warrants	(348,637)	(319,204)
Total other expenses	(762,571)	(229,965)
Net loss before provision for income taxes	(4,562,783)	(2,666,506)
Provision for income taxes
Net loss	(4,562,783)	(2,666,506)
Net loss attributable to the non-controlling interest	90,258	193,372
NET LOSS ATTRIBUTABLE TO BIOXYTRAN	$ (4,472,525)	$ (2,473,134)
Loss per Common share, basic	$ (0.03)	$ (0.02)
Loss per Common share, diluted	$ (0.03)	$ (0.02)
Weighted average number of Common shares outstanding, basic	133,973,352	112,712,305
Weighted average number of Common shares outstanding, diluted	133,973,352	112,712,305